The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2024

Filed:

Feb. 05, 2021
Applicant:

Tagworks Pharmaceuticals B.v., Eindhoven, NL;

Inventors:

Marc Stefan Robillard, Eindhoven, NL;

Hendricus Marie Janssen, Eindhoven, NL;

Wolter Ten Hoeve, Assen, NL;

Ronny Mathieu Versteegen, Hegelsom, NL;

Raffaella Rossin, Eindhoven, NL;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 257/02 (2006.01); C07D 257/08 (2006.01); C07D 237/26 (2006.01); C07C 33/16 (2006.01); A61K 47/68 (2017.01); A61K 47/54 (2017.01); B82Y 5/00 (2011.01); A61K 31/704 (2006.01); A61K 38/05 (2006.01); A61K 39/395 (2006.01); A61K 47/22 (2006.01); A61K 31/435 (2006.01); A61K 31/444 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6803 (2017.08); A61K 31/435 (2013.01); A61K 31/444 (2013.01); A61K 31/704 (2013.01); A61K 38/05 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 47/22 (2013.01); A61K 47/545 (2017.08); A61K 47/555 (2017.08); A61K 47/558 (2017.08); A61K 47/6897 (2017.08); B82Y 5/00 (2013.01); C07C 33/16 (2013.01); C07D 237/26 (2013.01); C07D 257/08 (2013.01); Y02A 50/30 (2018.01);
Abstract

The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.


Find Patent Forward Citations

Loading…